SCHEMBL21481783

SCHEMBL21481783

O=C(NC1CCC(C(=O)O)CC1)c1ccc(F)c2ccn(Cc3ccc(N4CCOCC4)cc3)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 6/20 0.39
▸ CNR2 P34972 6/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ LIPG Q9Y5X9 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ FLT3 P36888 1/20 0.39
▸ TYRO3 Q06418 1/20 0.39
▸ MERTK Q12866 1/20 0.39
▸ GAS6 Q14393 1/20 0.39
▸ MAPT P10636 1/20 0.38
▸ BMPR1B O00238 1/20 0.37
▸ BMPR1A P36894 1/20 0.37
▸ TGFBR1 P36897 1/20 0.37
▸ ACVRL1 P37023 1/20 0.37
▸ ACVR1 Q04771 1/20 0.37
▸ P2RX3 P56373 1/20 0.37
▸ PDE7A Q13946 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21485581 0.90 KDM4E (0.40) CNR1CNR2KDM4ENPC1RAB9A
SCHEMBL21458170 0.90 PTGER4 (0.40) CNR1CNR2KDM4ELIPGNPC1
SCHEMBL22927023 0.86 CNR2 (0.48) CNR1CNR2
SCHEMBL21485567 0.86 S1PR3 (0.41) CNR1CNR2LIPGP2RX3
SCHEMBL21506586 0.86 CNR2 (0.43) CNR1CNR2
SCHEMBL21506172 0.86 CNR2 (0.43) CNR1CNR2
SCHEMBL21481825 0.85 CNR2 (0.47) CNR1CNR2NPC1RAB9AKMT2A
SCHEMBL31203159 0.84 CNR2 (0.40) CNR1CNR2KDM4ENPC1RAB9A
SCHEMBL26616365 0.84 CNR1 (0.39) CNR1CNR2KDM4ELIPGNPC1
SCHEMBL21506741 0.83 MEN1 (0.43) CNR1CNR2KMT2AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10968201-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2021-04-06 — — US disclosed
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2021-01-28 — — US disclosed
WO-2019204523-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. (US) 2019-10-24 — — WO disclosed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10968201-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 CNR1 6/4885CNR2 3/4885KDM4E 719/4885
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CNR1 6/4885CNR2 3/4885KDM4E 719/4885
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CNR1 6/4885CNR2 3/4885KDM4E 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback